Drug Channels

MAY 25, 2021

Summer unofficially begins this weekend! P.S. Join the nearly 11,800 followers of my daily links to neat stuff at @DrugChannels on Twitter. You can also follow me on LinkedIn. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Pharmacy 52

Pharmacy Drugs Marketing 52

The Pharma Data

SEPTEMBER 11, 2020

In broader pharmaceutical news, Takeda has revealed it has agreed to divest its non-core portfolio of prescription therapies to Cheplapharm in exchange for an upfront payment of $562 million, while Mylan has announced an agreement to acquire the intellectual property and commercialisation rights to Aspen’s thrombosis business for €641.9

Vaccination 52

Vaccination Vaccine FDA Approval Clinical Trials 52

Pharma in Brief

MARCH 27, 2023

No special market exclusivity rights Canada’s rare disease strategy does not address any intellectual property or market exclusivity rights targeted to encourage access for rare disease drugs. new treatments for rare disease can be designated an “orphan product” eligible for a seven year period of market exclusivity after approval.

Drugs 52

Drugs Marketing Clinical Trials Clinical Trials 52

pharmaphorum

FEBRUARY 16, 2021

A news agency is claiming that North Korea launched a cyber-attack on Pfizer in a bid to steal information about its BioNTech-partnered COVID-19 vaccine, citing South Korea’s National Intelligence Service (NIS). And last year, Europol warned that criminal networks were exploiting the COVID-19 pandemic with a surge in cybercrime.

Vaccination 108

Vaccination Vaccine Pharma Companies Development 108

pharmaphorum

NOVEMBER 24, 2021

BIO-ISAC thinks the motivation may be espionage and theft of intellectual property, as well as an attempt to disrupt operations – and reckons that the group behind it is well-funded and may even be state-backed. Worryingly, the malware seems to be specifically designed and targeted to biomanufacturing facilities, it said.

Production 78

Production Vaccination Vaccine Engineer 78

The Pharma Data

JANUARY 12, 2021

With the phase of the Agreement relating to the development of the antibody completed, under the Agreement, as of 11 January 2021, GlobalCo has three months to exercise an option to license the Company’s intellectual property necessary to exploit the CDX antibody on an exclusive worldwide basis (“Option”).

Antibody 40

Antibody Development Licensing Licensing 40

Pharmacy Checkers

JULY 2, 2019

In many cases, patented products are imported by patients where there is no intellectual property violation. In those instances, Article 60 of the WTO’s Trade Related Intellectual Property Rights agreement strongly discourages enforcement actions against such personal imports. Kaiser Health News, December 20, 2016.

Medicine 49

Medicine Pharmacy Regulation Insulin 49

The Pharma Data

DECEMBER 14, 2020

“BetterLife’s acquisition of Transcend’s intellectual property allows us a rapid pathway forward to drug manufacturing and human clinical studies without the regulatory hurdles seen elsewhere in this industry,” stated Dr. Ahmad Doroudian, Chief Executive Officer of BetterLife. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS.

Drug Delivery 40

Drug Delivery Containment Manufacturing Drugs 40

The Pharma Data

DECEMBER 23, 2020

Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. or Europe to avoid off label prescription writing.

Containment 52

Containment Regulation Compliance Development 52

Drug Discovery World

SEPTEMBER 26, 2022

However, with a few years having passed now since the beginning of the pandemic, pharmaceutical companies are now looking more closely at their respective intellectual property (IP) in the case of Covid-19 vaccines. Moderna alleges that Pfizer and BioNTech copied this technology, without Moderna’s permission, to make Comirnaty.

Vaccination 52

Vaccination Vaccine Life Science Sales 52

The Pharma Data

OCTOBER 15, 2020

We believe the preliminary survival curves are very similar to the original MSK data, and this is good news for children with CNS/leptomeningeal metastasis from neuroblastoma,” said Claus Moller, Chief Executive Officer. Researchers at MSK developed naxitamab and omburtamab, which are exclusively licensed by MSK to Y-mAbs.

Production 52

Production Development Marketing Licensing 52

The Pharma Data

MAY 13, 2021

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. . China backs talks on intellectual property waiver for COVID vaccines ( Reuters ). ‘Dude, you’re getting a Dell’ — as a new deep-pocket biotech investor ( Endpoints ). In Focus: US.

FDA Approval 52

FDA Approval Vaccination Vaccine Drugs 52

Drug Discovery World

NOVEMBER 24, 2023

This means durvalumab was granted intellectual property (IP) and included in the Innovative Licensing and Access Pathway (ILAP), which aims to reduce the time it takes innovative treatments to be made available to NHS patients. 6 Initial data reported a median overall survival of 12.8 0.97, p=0.021). 9 An additional 6.5 months to 12.9

HR 52

HR Licensing Licensing Trials 52

The Pharma Data

FEBRUARY 1, 2021

Biogen Safe Harbor This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to the potential benefits, safety and efficacy of Plegridy; and the results of certain real-world data. Securities and Exchange Commission.

FDA Approval 40

FDA Approval Bioequivalency Clinical Trials Clinical Trials 40

The Pharma Data

JUNE 25, 2021

These statements are based on Biogen’s current beliefs and expectations and speak only as of the date of this news release. . There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. Securities and Exchange Commission.

Antibody 40

Antibody Clinical Trials Clinical Trials Development 40

The Pharma Data

DECEMBER 29, 2020

The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Drugs 52

Drugs Regulation Marketing Production 52

The Pharma Data

JULY 8, 2021

These statements are based on Biogen’s current beliefs and expectations and speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. For more information about Eisai Co.,

Clinical Trials 52

Clinical Trials Clinical Trials FDA Approval Trials 52

The Pharma Data

OCTOBER 26, 2020

This information is provided by RNS, the news service of the London Stock Exchange. This work complements the Company’s own development work currently being undertaken. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

Development 40

Development Antibody Engineer Production 40

The Pharma Data

NOVEMBER 17, 2021

Through its innovative business model, MPP mates with civil society, governments, transnational associations, assiduity, patient groups, and other stakeholders, to prioritize and certify demanded drugs and pool intellectual property to encourage general manufacture and the development of new phrasings.

Licensing 52

Licensing Licensing Medicine Manufacturing 52

The Pharma Data

NOVEMBER 9, 2020

Dr. Löbenberg with respect to exclusive commercial development rights under his cannabis licences and to related intellectual property. This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law (“forward-looking statements”). Source link.

Development 40

Development Drugs Drug Delivery Production 40

The Pharma Data

NOVEMBER 4, 2020

His broad leadership experience in the pharmaceutical industry, from intellectual property and regulatory compliance to product manufacturing and distribution, presents an exciting opportunity for XPhyto,” said Hugh Rogers, CEO of XPhyto. Thoresen is an important addition to XPhyto’s board of directors. Source link.

Drug Delivery 40

Drug Delivery Production Manufacturing Life Science 40

The Pharma Data

JULY 27, 2021

Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter , Facebook , Instagram , YouTube and LinkedIn.

Life Science 52

Life Science Development Research Production 52

The Pharma Data

OCTOBER 29, 2020

These statements are based on Biogen’s current beliefs and expectations and speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. For more information about Eisai Co.,

Medicine 40

Medicine Marketing Clinical Trials Clinical Trials 40

The Pharma Data

JULY 29, 2021

These statements are based on Biogen’s current beliefs and expectations and speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. Securities and Exchange Commission.

Clinical Trials 52

Clinical Trials Clinical Trials Development Antibody 52

The Pharma Data

DECEMBER 9, 2020

These statements are based on Biogen’s current beliefs and expectations and speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. For more information about Eisai Co.,

Drugs 40

Drugs Clinical Trials Clinical Trials Development 40

The Pharma Data

NOVEMBER 6, 2020

These statements are based on Biogen’s current beliefs and expectations and speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. For more information about Eisai Co.,

Clinical Trials 40

Clinical Trials Clinical Trials Licensing Licensing 40

Roots Analysis

NOVEMBER 3, 2023

Several factors have contributed to the failure of NAMPT inhibitors in clinical trials, including poor pharmacokinetic properties, limited efficacy, and toxicity issues. Recently, Ronit’s expertise has been recognized by the online news agency, where he was interviewed and featured as an emerging industry leader. Ronit holds a B.

Development 40

Development Drugs Trials FDA Approval 40

The Pharma Data

SEPTEMBER 17, 2020

To learn more about Lilly , please visit us at lilly.com and lilly.com/news. Amgen Forward Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen.

Antibody 52

Antibody Manufacturing Production Sales 52

XTalks

MARCH 14, 2022

two fungi-based alt meat companies, are embroiled in a legal battle over their alt meat intellectual property (IP). Meati Foods and The Better Meat Co. , Meati has accused Better Meat of stealing its mycelium harvesting tech, while Better Meat has accused Meati of damaging its reputation and fundraising efforts in a separate lawsuit.

Protein 98

Protein FDA Approval Development Production 98

The Pharma Data

JULY 27, 2021

Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S.

Production 52

Production Antibody Sales Manufacturing 52

The Pharma Data

NOVEMBER 4, 2020

New CTP-543 Data Presented in Late-Breaking News Session at EADV 2020. Initial data from an ongoing long-term, open label extension study with CTP-543 were presented in the late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Virtual Congress on October 29, 2020.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Dermatology 52

pharmaphorum

NOVEMBER 10, 2021

Moderna has come in for criticism for supplying its vaccine mainly to affluent countries and not making the intellectual property for the vaccine available to other producers who could make it more cheaply.

Vaccination 87

Vaccination Vaccine Scientist Protein 87

World of DTC Marketing

APRIL 25, 2021

QUICK READ:There are times when I really want to quit working in the industry and the latest news about pharma is aiming at U.S. lawmakers to stop the global push to lift intellectual property through a waiver for Covid vaccines is just the latest.

Vaccination 194

Vaccination Vaccine Development Production 194

Pfizer

FEBRUARY 16, 2023

In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

The Pharma Data

JULY 21, 2021

Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter , Facebook , LinkedIn or Instagram.

Production 52

Production Doctors Doctor Medicine 52

The Pharma Data

DECEMBER 13, 2020

A webcast of the conference call will be available under “News and Presentations” in the Investors & Media section of Relay Therapeutics’ website at [link]. To access the live call, please dial 1 (833) 540-1168 (domestic) or 1 (929) 517-0359 (international) and refer to conference ID 8792127.

Licensing 40

Licensing Licensing Clinical Trials Clinical Trials 40

The Pharma Data

JULY 21, 2021

Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter , Facebook , Instagram , YouTube and LinkedIn.

Medicine 52

Medicine Vaccination Vaccine Clinical Trials 52